Overview

Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes

Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
To evaluate response rate of cisplatin - metronomic cyclophosphamide treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Jean Perrin
Treatments:
Cisplatin
Cyclophosphamide